Global

The rare disease market in China can be summed up in three words: Exciting, challenging, and fast evolving. As such it’s quite a complicated space that requires a careful and strategic approach. In this article experts from Simon-Kucher discuss how best to navigate this landscape to reap the many opportunities available.

And, in equal measure, patients and doctors—as EU mulls new rules.

Proposed SoHO reform elicits wide support, but risks acknowledged.

Jimenez discusses bringing care to diverse and underserved communities.

Industry leaders discuss new technologies, research, and investment strategies.

Continent has shed its ‘emerging’ status on world biopharma stage.

Legislative-reform alliance makes for strange bedfellows.

Group’s ideas to change EU pricing rules draw captive audience.

Investments setting up sector for future success that could one day rival its US counterpart.

Kalidas spoke with Pharm Exec about her efforts to bring equity to underserved patients and their communities through Bayer’s Oncology Sustainability Initiative.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.

Recent growth in pharma makes Ireland an ideal candidate for expansion opportunities.

The risky business of outmaneuvering Europe’s drug pricing authorities.

Brexit and the pandemic continue to complicate flow of international talent.

This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.

Exploring the market’s emergence on the global stage.

Fresh round of discussions around health technology assessment.

Efforts for a standardized approach coming to a head in Europe.

Witkos discusses her achievements during her first year as SVP, International Region head, and her long-term goals in helping to maintain Alnylam’s leadership in the RNAi field.

Increase in new treatments also brings increase in logistical challenges for pharma.

Assessing the road ahead for Chinese biotech.

Opportunity remains despite regulatory and access obstacles.

Licensing deals, strategy, and COVID among factors to consider for companies entering Chinese pharma M&A.

Emma Thorp and Mel Walker, PhD, of RBW consulting discuss European strategy for US biotechs.

With a strong pharma background that includes bringing non-US biotechs stateside in the rare diseases space, Rami Levin, CEO of Saniona, talks about the importance of growing his company’s business and his dedication to that mission.

European Commission looks to relieve issues without legislation.

Forging effective partnerships with local companies is particularly important when entering Brazil’s pharma market. Sameer Kolhe reports.

Looks to address disconnect between registration and reimbursement.

2021‘s Pharmaceutical Industry Network Group (PING) conference focused on the UK’s COVID-19 response and how it can continue as a leader in science innovation and collaboration, including opportunities through use of health and genomic data.